Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Exercise training as prophylactic strategy in the management of neutropenia during chemotherapy

Publikation: Bidrag til tidsskriftReviewpeer review


  1. Advances in migraine and headache therapy (BJP 75th anniversary)

    Publikation: Bidrag til tidsskriftLederpeer review

  2. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Metabolic control and sex: A focus on inflammatory-linked mediators

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

Chemotherapy-induced immune-suppression is a common, but potential detrimental, adverse reaction in patients undergoing treatment for cancer and strategies with capacity to boost the immune cell populations are needed. Physical exercise training is a potent regulator of immune cell viability and function and may serve as a viable, non-pharmacological prophylactic strategy in addition to the current pharmacological management by, for example, granulocyte-colony stimulating factor (G-CSF). Here, we review the mechanistic evidence linking exercise training to haematopoietic function and subsequent possible amelioration of chemotherapy-related neutropenia. First, we briefly describe neutrophil regulation and management of neutropenia in cancer patients. Second, we summarize the effect of acute and chronic exercise training on neutrophils and their progenitors, and finally, we outline the current clinical evidence of exercise interventions in ongoing anti-cancer treatment in regard to neutropenia incidence, treatment tolerance and related outcomes. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit

TidsskriftBritish Journal of Pharmacology
Udgave nummer12
Sider (fra-til)2925-2937
Antal sider13
StatusUdgivet - jun. 2022

Bibliografisk note

© 2020 The British Pharmacological Society.

ID: 78317637